All News

Cardinal Innovations Healthcare is the largest specialty health plan in the country, insuring more than 850,000 North Carolinians with complex needs. Using a community-based model of care management, Cardinal Innovations has led the way in developing services, processes and solutions that improve the lives of our members and their families. Recognized for operational excellence, innovative solutions and superior outcomes for members, accuracy and speed of payments to providers, and cost-effective funds management, Cardinal Innovations is a leading healthcare company in the United States.

Radium-223’s (Ra-223) low levels of alpha particle radiation induce double-strand DNA breaks, which leads to cell apoptosis. Sipuleucel-T (SipT), which is an immunotherapy manufactured from a patient’s peripheral blood mononuclear cells, activates T cells to spur an immune response. Both are used to treat bone-metastatic castration-resistant prostate cancer (CRPC). Study data suggest a synergistic immune effect when Ra-223 is added to treatment with SipT.

According to recent study results published in JAMA, treatment-limiting Physician Orders for Life-Sustaining Treatment (POLSTs) were significantly associated with lower rates of intensive care unit admissions among patients with life-limiting conditions compared with patients who had full-treatment POLSTs. However, researchers found 38% of patients with treatment-limiting POLSTs still received intensive care that was potentially discordant with their preferences.

Michael Abrams, MA, is the co-founder and managing partner of Numerof & Associates, a firm that helps businesses across the healthcare industry define and implement strategies for winning in dynamic markets. He has more than 25 years of expertise working helping clients navigate an evolving healthcare landscape, across hospital systems, payers, and Fortune 500 pharmaceutical, device, and diagnostics companies. He has co-authored several books and has been featured in leading business journals and news outlets.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text